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Abstract
Background: Primary congenital glaucoma (PCG) and early onset glaucomas are one of the major causes of
children and young adult blindness worldwide. Both autosomal recessive and dominant inheritance have been
described with involvement of several genes including CYP1B1, FOXC1, PITX2, MYOC and PAX6. However, mutations in
these genes explain only a small fraction of cases suggesting the presence of further candidate genes.
Methods: To elucidate further genetic causes of these conditions whole exome sequencing (WES) was performed in
an Italian patient, diagnosed with PCG and retinal detachment, and his unaffected parents. Sanger sequencing of the
complete coding region of COL1A1 was performed in a total of 26 further patients diagnosed with PCG or early onset
glaucoma. Exclusion of pathogenic variations in known glaucoma genes as CYP1B1, MYOC, FOXC1, PITX2 and PAX6 was
additionally done per Sanger sequencing and Multiple Ligation-dependent Probe Amplification (MLPA) analysis.
Results: In the patient diagnosed with PCG and retinal detachment, analysis of WES data identified compound
heterozygous variants in COL1A1 (p.Met264Leu; p.Ala1083Thr). Targeted COL1A1 screening of 26 additional patients
detected three further heterozygous variants (p.Arg253*, p.Gly767Ser and p.Gly154Val) in three distinct subjects: two of
them diagnosed with early onset glaucoma and mild form of osteogenesis imperfecta (OI), one patient with a
diagnosis of PCG at age 4 years. All five variants affected evolutionary, highly conserved amino acids indicating
important functional restrictions. Molecular modeling predicted that the heterozygous variants are dominant in effect
and affect protein stability and thus the amount of available protein, while the compound heterozygous variants act as
recessive alleles and impair binding affinity to two main COL1A1 binding proteins: Hsp47 and fibronectin.
Conclusions: Dominant inherited mutations in COL1A1 are known causes of connective tissues disorders such as OI.
These disorders are also associated with different ocular abnormalities, although recognition of the common pathology
for both features is seldom being recognized. Our results expand the role of COL1A1 mutations in different forms of
early-onset glaucoma with and without signs of OI. Thus, we suggest including COL1A1 mutation screening in the
genetic work-up of glaucoma cases and detailed ophthalmic examinations with fundus analysis in patients with OI.
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Background
Primary congenital glaucoma (PCG, OMIM 231300) is
the most common type of childhood glaucoma due to
the abnormal development of structures in the anterior
segment of the eye including the trabecular meshwork,
Schlemm’s canal and the anterior chamber angle. It
manifests during neonatal or early infantile period
(before 3 years of age) and is characterized by ele-
vated intraocular pressure (IOP), increased corneal
diameter, enlarged globe, Haab’s striae, corneal edema,
and optic nerve head cupping. Symptoms are photo-
phobia, ephiphora and blepharospasm [1]. PCG repre-
sents a diagnostic and therapeutic challenge as it can
lead to irreversible blindness in the first years of life
if untreated.
Inheritance is primarily autosomal recessive, although
pedigrees with dominant inheritance or sporadic cases
have been described [2]. Several chromosomal loci have
* Correspondence: francesca.pasutto@uk-erlangen.de
2Institute of Human Genetics, Friedrich-Alexander-Universität
Erlangen-Nürnberg (FAU), Erlangen, Germany
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Mauri et al. Orphanet Journal of Rare Diseases  (2016) 11:108 
DOI 10.1186/s13023-016-0495-y
been so far mapped for the recessive form of PCG, but
up to now only two genes have been identified: cyto-
chrome P4501 subfamily 1B1 (CYP1B1, OMIM 601771)
on the GLC3A locus and latent transforming growth fac-
tor beta binding protein 2 (LTBP2, OMIM 602091) on
the GLC3D locus. CYP1B1 is the most common identifi-
able cause of PCG worldwide. In the European popula-
tion the prevalence of CYP1B1 mutations ranges from
20 to 30 % of all PCG cases [3]. In contrast, LTBP2 mu-
tations in classical cases of PCG are much rarer, being
reported only for a few cases from Pakistan and in pa-
tients of Gypsy ethnicity [4].
Mutations in CYP1B1 can infrequently underlie the
autosomal dominant, juvenile open-angle glaucoma
(JOAG, OMIM 137750) and even adult-onset forms of
primary open-angle glaucoma (POAG, OMIM 137760)
[5]. However, across most populations, the most com-
mon identifiable cause of JOAG remains heterozygous
mutations in myocilin gene (MYOC, OMIM 601652),
underlying up to 7–15 % of cases. JOAG manifests in
the first decades of life and is characterized by elevated
IOP, progressive glaucomatous optic neuropathy, severe
visual field defects (VFD) and is frequently associated
with severe myopia [6].
A further autosomal dominant form of infantile/de-
velopmental glaucoma is a phenotypic aspect of ocu-
lar anterior segment dysgenesis (ASD), a genetically
heterogeneous group of complex developmental disorders
including Axenfeld-Rieger’s anomaly, Peters’ anomaly,
aniridia, iris hypoplasia and iridogoniodysgenesis [7].
Approximately 50 % of individuals with ASD generally de-
velops glaucoma due to malformations of tissues respon-
sible for the IOP regulation and aqueous humor drainage
including the iris, cornea, lens, Schlemm’s canal and tra-
becular meshwork (TM) [7, 8]. Due to the malformations
in Schlemm’s canal and TM, PCG is sometimes grouped
together with the ASD disorders. In ASD glaucoma may
develop during childhood (developmental glaucoma), but
it is more common during adolescence or at the beginning
of adulthood (early-onset glaucoma). Glaucoma associated
with ASD progresses rapidly, is difficult to manage and
may result in severe damage of the optic disc and visual
field [9]. To date mutations in Forkhead Box C1 (FOXC1,
OMIM 601090), Paired-Like Homeodomain transcription
factor 2 (PITX2, OMIM 601542), and Paired Box Gene 6
(PAX6, OMIM 607108) genes are the most common cause
of glaucoma in ASD [8]. Interestingly, mutations in
CYP1B1 are also associated with rare cases of Peters’
anomaly.
Currently, mutations in six genes, CYP1B1, LTBP2,
MYOC, PITX2, FOXC1 and PAX6, can explain only a
fraction of all congenital/infantile/early-onset glaucoma
cases worldwide suggesting the involvement of other
candidates [10].
The identification of disease-causing variants in
known or novel genes in children with glaucoma can
have a significant impact on establishing proper diag-
nosis, disease risk assessment and clinical care. In
fact, variable expressivity, phenotypic overlap and lim-
ited follow-up among these different early-onset glau-
coma forms have often led to an incorrect or delayed
definitive diagnosis. Moreover subsequent treatment
may be inadequate because of advanced disease. As a
consequence childhood glaucoma still causes a dispro-
portionately high percentage of childhood blindness
worldwide. Hence, an early and reliable diagnosis is
essential to prevent unwanted vision loss and also to
reduce the burden of childhood blindness [11].
Whole exome sequencing has been demonstrated to
be highly successful in identifying disease-causing vari-
ants in rare ocular diseases [12, 13]. Thus, we decided to
apply this approach to selected cases of congenital/in-
fantile glaucoma presenting no disease-causing variants
in the known associated genes.
Here, we report on the novel association of com-
pound heterozygous variants in collagen type I alpha
1 gene (COL1A1, OMIM 120150) in one patient diag-
nosed with PCG and retinal detachment. Further-
more, three COL1A1 heterozygous variants were
identified in three patients: two with an early onset
glaucoma form and one with congenital glaucoma,
two of them presenting also an early-onset cataract
and mild form of osteogenesis imperfecta (OI). In
addition, we provide protein modeling based evidence
for the pathogenicity of the variants identified.
Altogether, these findings expand the role of COL1A1
in different forms of developmental/early onset glau-
coma and show that disease-causing variants in
COL1A1 may act also as recessive alleles confirming
data of previous mouse models [14]. In addition, our
results support and double the number of patients in
the literature with glaucoma observed in osteogenesis
imperfecta (OI) [15] and serve to advise that glaucoma
is also an important complication of OI.
Methods
Patients’ data
To identify the genetic basis of a rare form of PCG with
retinal detachment, an Italian patient and his unaffected
parents were selected for whole exome sequencing ana-
lysis. Additionally, to detect further disease-causing vari-
ants in COL1A1 gene, 24 unrelated German patients
diagnosed with PCG or infantile glaucoma in the first
year of life [16] and two patients, one from Germany
[17] and one from USA respectively, diagnosed with ju-
venile glaucoma and OI underwent variants screening of
the COL1A1 coding regions by Sanger sequencing.
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Ophthalmological examinations included visual acuity
measurements, tonometry and fundoscopy. PCG was de-
fined by the following characteristics: (i) age of onset less
than 3 years, (ii) increased corneal diameter greater than
10 mm accompanied by corneal edema and/or Haab
striae and (iii) IOP greater than 21 mmHg and/or optic
nerve cupping greater than 0.4. Any patient with other
ocular abnormalities or systemic conditions, other than
iris stromal hypoplasia, was excluded from the study.
JOAG was defined when typical glaucomatous visual
field (VF) loss on Octopus or Humphrey perimetry and
glaucomatous alterations of the ONH were present with
age of onset less than 40 years old and IOP greater than
21 mmHg.
DNA extraction and Sanger sequencing analysis
Peripheral blood samples were obtained from all individ-
uals and genomic DNA was extracted according to
standard procedures (Flexi-Gene Kit (Qiagen, Germany).
Complete coding region of the CYP1B1, MYOC, FOXC1,
PITX2, PAX6 and COL1A1 genes including flanking in-
tronic/UTR sequences were amplified by polymerase
chain reaction (PCR) using appropriate amplification
protocols. Primer sequences were selected using Primer3
software [18] and can be found in Additional file 1.
Conditions used to amplify these coding regions can
be provided on request. Purified PCR fragments were
sequenced using Big Dye v.3.1 (Applied Biosystems,
ABI, Weiterstadt, Germany) on an automated capillary se-
quencer, according to the manufacturer’s instructions
(ABI 3730 Genetic Analyzer, Weiterstadt, Germany. Se-
quences were analysed using Sequencer5.1 (Gencodes)
and SeqPilot (JSI medical systems) softwares. GenBank
Accession Numbers NM_000104.3, NM_000261.1,
NM_001453.2, NM_001204398.1, NM_001258462.1 and
NM_000088.3 were used as reference sequences for
CYP1B1, MYOC, FOXC1, PITX2, PAX6 and COL1A1 re-
spectively [19], with +1 corresponding to the A of the
translation initiation codon ATG in the cDNA nomencla-
ture, according to the Human Genome Variation Society
(HGVS) nomenclature guidelines.
To detect the presence of CYP1B1, FOXC1, PITX2 and
COL1A1 exon rearrangements (deletion/duplication),
multiplex ligation-dependent probe amplification (MLPA)
assay (Kit-P54, P128, P219 and P271, MRC-Holland,
Amsterdam, Netherlands) was used according to the
manufacturer’s protocol. Raw data were analysed
using MLPA-module of the Sequence Pilot software
(JSI medical systems).
Analysis of amino acid conservation
Evolutionary conservation of mutated amino acids was
investigated with protein sequence alignment generated
by Clustal Omega [20] and compared with data provided
by UCSC Database [21].
Whole-Exome Sequencing (WES)
For whole exome sequencing of the initial patient
(ID: MI-1) and his unaffected parents, DNA samples
were enriched using the SureSelect Human All Exon
Kit version 5 (Agilent, Santa Clara, CA) and paired-
end sequenced (75 bp forward, 25 bp reverse) on a
SOLiD5500xl instrument (Life Technologies, Carlsbad,
CA). Image analysis and colour calling was performed
using the SOLiD instrument control software with default
parameters. Read alignment to the human reference gen-
ome assembly (GRCh37/ hg19) was performed with Life-
Scope 2.5 using the default parameters. For the three
samples, we achieved average sequence coverage of 133×
(minimum 126×). On the average, 87.9 % (minimum
87.6 %) of the target sequence was covered at least 20×
and 94.0 % (minimum 83.9 %) was covered at least 5×.
Variants and small insertions and deletions (indels) were
called using diBayes (part of LifeScope), the LifeScope
small indel caller, ATLAS2-indel [22], Genome Analysis
Toolkit (GATK2) and samtools/bcftools [23–25]. Variant
annotation was performed using ANNOVAR [26] in con-
junction with a variety of open and proprietary annotation
database files: SIFT v. 1.03 [27], PolyPhen2 [28] and Muta-
tionTaster [29] were used for prediction of amino acids
substitution; entries of dbSNP132 and of the 1000 Ge-
nomes Project [30] were used to check alleles frequencies.
Graphical presentation of the mapped sequences was
viewed with the integrative genomics viewer (IGV, [31]). A
total of 86,588 variants were called, of which 3,353 were
indels and 83,235 were single nucleotide variants. Based
on the supposed rare incidence of the phenotype we ex-
cluded all frequent variants (above 0.01 %), detected in
any of the 997 in-house control individuals of Caucasian
origin as well as all annotated variants of dbSNP132, the
1000genomes project, and the exome variant server
(http://evs.gs.washington.edu/EVS). Excluding intergenic,
intronic and synonymous variants led to a total of seven
remaining, variants in five genes proposing an autosomal
recessive, X-recessive and de novo inheritance (Table 1).
Based on Exome Aggregation Consortium frequencies
data (ExAC, [32]) on the mutational effect of these vari-
ants, their conservation (PhyloP, GERP++) and prediction
program scores of SIFT, PolyPhen2 and MutationTaster,
CADD, four variants in three candidate genes remained as
putative candidate variants (Table 1). Based on available
knowledge annotated in different public databases as
NCBI, UCSC and MGI [33–35], candidate variants in AR
and FMNL2 gene were excluded as these two genes could
not be related to the patient phenotype. Thus, only the
two variants in COL1A1 gene remained as putative
candidate variants for the given patient phenotype:
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Table 1 List of the exome candidate variants identified in the patient MI-1




COL1A1 chr17 48265471 NM_000088.3 44 c.3247G>A p.(Ala1083Thr) 7,7E-05 rs372029024 3,277E-05 6,631E-05 1.212 0,09 P D D 4,29 14,23
COL1A1 chr17 48274385 NM_000088.3 11 c.790A > T p.(Met264Leu) 7,7E-05 rs374947065 8,132E-06 1,477E-05 1.952 0,58 B D D 5,19 11,54
EXPH5 chr11 108382912 NM_001144763.1 6 c.3094A > T p.(Thr1032Ser) 0 1,627E-05 2,967E-05 0,065 0,27 B N N 1,75 10,15
EXPH5 chr11 108382329 NM_001144763.1 6 c.3677C >G p.(Thr1226Arg) 0 8,132E-06 1,481E-05 0,372 0,27 B N N 2,91 10,69
X-Rec.
AR chrX 66766013 NM_000044.2 1 c.1025C > T p.(Pro342Leu) 0 0 0 2.317 0,18 D N D 4,09 14,24
IL1RAPL2 chrX 104440391 NM_017416.1 3 c.317C > T p.(Ala106Val) 0,002461 rs144175494 0,001008 0,0017 1.081 0,48 B N D 3,35 14,42
De Novo
FMNL2 chr2 153473665 NM_052905.3 13 c.1273A >G p.(Lys425Glu) 0 0 0 2.231 0,6 D D N 5,04 25,2
Main candidate variants are evidenced in bold. Chrom Chromosome, EVSFreq Exome Variant Server frequency (NHLBI Exome sequencing Project, ESP), ExAC02 ExAC Browser (Beta), Exome Aggregation Consortium, Eur European














one missense mutation c.790A > T (NM_000088.3:
p.(Met264Leu)) in exon 11 and a second missense
mutation c.3247G > A (NM_000088.3: p.(Ala1083Thr))
in exon 44 c.662C > T of the COL1A1 gene. Both var-
iants could be validated by Sanger sequencing and
segregation was confirmed inside the family (Fig. 1).
The unaffected parents are each one carrier of one of
the two variants. In addition, both variants are absent
in the healthy brother (Fig. 1). No further variants in
any of the known glaucoma genes or other potential
candidate genes were identified in this individual.
Therefore, the identified variants in COL1A1 gene are
highly likely to be pathogenic.
Molecular modelling
Mutations in collagen were modelled based on the crys-
tal structures of isolated collagen (PDB: 3HQV [36]),
collagen in complex with fibronectin (PDB: 3GXE [37]),
or collagen in complex with Hsp47 (PDB: 3ZHA [38]).
Amino acid exchanges were introduced with SwissModel
[39]. Ligplot and Whatcheck were used for structure
analysis [40, 41] and RasMol [42] was used for structure
analysis and visualization [43].
Results
Identification of COL1A1 variants
In this study, the first patient (ID: MI-1) is an Italian
15 year old male (Fig. 1) who was diagnosed with bilat-
eral PCG at 4 months of age. He presented bilateral
Buphthalmus, deformed ocular bulbs, corneal edema,
corneal opacity, Haab’s striae, elevated IOP (40 mmHg
right eye and 28 mmHg left eye, Goldmann applanation
tonometry), thinning of optic nerve and ocular muscles.
Following bilateral trabeculoctomy ab externo at the age
of 6 months, the IOP was kept under control with
pharmacologic therapy (Dorzolamide and Timolol). Be-
tween age 1 and 5 years he developed a high myopia
(14–18 diopters, best corrected visual acuity, BCVA: 1/50
in the left and 2/10 in the right eye). At the age of six he
had almost complete loss of vision with only light percep-
tion in the left eye and BCVA 1/25 in the right eye. In
addition, as the proposed pharmacological therapy
(Dorzolamide, Acetozulamide XR, Timolol, Travapost,
Latanoprost and Brimonidine tartrate) failed in keeping
the IOP under control, he underwent a further bilateral
trabeculoctomy ab externo. Retinal detachment first in the
right eye (at age 7 years) and then in the left eye (at age of
11 years) led to a complete loss of vision in both eyes des-
pite scleral buckling and cryocoagulation surgery. Electro-
retinography (ERG) showed absent light response and
Visual Evoked Potential (VEP) signals were completely ex-
tinct due to severe axonal damage. Both parents were
healthy, without any pathological ocular phenotype.
Given the first diagnosis of PCG, mutations in CYP1B1
and MYOC were excluded by conventional Sanger se-
quencing as well as deletions in CYP1B1 by MLPA ana-
lysis. WES of DNA samples obtained from the patient
and his unaffected parents was then carried out in order
Fig. 1 COL1A1 mutation identified in first patient. a Pedigree, genotypes and DNA sequence chromatograms of affected child (black colored
symbol), his healthy parents and brother are reported. b Eyes of the patient at age 15: visible are Buphthalmus mainly present in the right eye
and corneal edema
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to identify novel disease causing genes. Variant analysis
of patient’s and his parents’ WES data (Table 1) revealed
two heterozygous candidate variants in the coding re-
gion of COL1A1 gene, c.790A > T and c.3247G > A,
which lead in the protein to the amino acid changes
p.(Met264Leu) and p.(Ala1083Thr), respectively. Direct
Sanger sequencing analysis on available family members
demonstrated that these variants were inherited each
one from one of the unaffected parents, confirming a re-
cessive mode of inheritance. Both variants were absent
in the healthy brother (Fig. 1) and could be excluded
from 1.994 in house-control chromosomes.
As mutations in COL1A1 gene are usually associated
with Osteogenesis Imperfecta (OI) we performed a lit-
erature search to find possible reported cases with OI
and associated glaucoma. We detected a case report on
a German patient diagnosed with open angle glaucoma
and a mild form of OI [17]. The described 61 year old
male patient (ID: MZ-2) presented with a bilateral blue,
thin and abnormally elastic sclera. Bilateral JOAG was
diagnosed at the age of 29 years as reported [17]. In
addition, he had an early onset cataract treated with
phacoemulsification and intraocular lens (IOL)-implant-
ation. The maximum IOP at age 54 years was 35 mmHg
under medical therapy and the central cornea thickness
(CCT) was extremely thin: 398 μm and 408 μm on the
right and left eye, respectively. There was bilateral
glaucomatous optic neuropathy and he was treated
with topical application of dorzolamid, brimonidin
and bimatoprost [17]. We had the opportunity to get
a DNA sample from this described patient (ID: MZ-2).
After exclusion of mutations in CYP1B1 and MYOC, we
identified by Sanger sequencing analysis of the COL1A1
complete coding region a heterozygous variant c.757C >T.
This variant introduces at protein level, a premature stop
codon at amino acid position 253: p.(Arg253*). The pres-
ence of a single heterozygous variant is in accordance with
an autosomal dominant inheritance model already re-
ported both for OI and for JOAG.
A further third patient from USA (ID: CA-3) was re-
ferred to us for mutation screening in COL1A1 gene.
The 62 year old female had a diagnosis of OI and open
angle glaucoma. The glaucoma was first diagnosed at
age 55 years, although it may have developed before and
not detected due to absence of detailed ophthalmic
examination. In fact, the patient was under pharmaceut-
ical therapy in both eyes (dorzolamide 2 % -timolol0.5 %
bid, travaprost .003 %qhs and brimonidine 0.15 %) for
elevated IOP, since 20 years. The glaucoma was reported
moderately advanced, worse in left than right eye. Re-
sults of visual field exams and optic nerve photograph
are shown in Fig. 2. Central corneal thickness was ex-
tremely thin (448 μm both on the right and left eye). At
age 62 years, the IOP was uncontrolled under maximum
tolerated medical therapy and then trabeculectomy was
undertaken on the left eye. External eye exam was
normal: i.e. she has no blue sclera and no corneal edema.
Concerning OI diagnosis, she reported that bone
changes began during adolescence and at age of 62 was
wheelchair dependent. Unfortunately, we have no clin-
ical data about the classification of OI type. As for pa-
tients ID: MZ-2, COL1A1 Sanger sequencing analysis
was performed also in this third patient (ID: CA-3) after
exclusion of mutations in MYOC and CYP1B1. As ex-
pected, sequencing analysis revealed a heterozygous vari-
ant, c.2299G > A, leading at protein level to the amino
acid change p.(Gly767Ser).
COL1A1 analysis of the complete coding region by
Sanger sequencing was then carried out in an inde-
pendent cohort of 24 German patients diagnosed with
congenital/early onset glaucoma that were found
negative for mutations in CYP1B1 and MYOC genes.
Fig. 2 Ophthalmic findings in patient CA-3: a–d Humphrey visual
fields of the third patient demonstrated early nasal field defects in
both eyes (a/c left eye and b/d right eye respectively). e–f Opthic
nerve photographs of patient CA-3 shown glaucomatous optic
nerve cupping in both eyes (e-left eye and f-right eye)
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This screening led to the identification of an add-
itional fourth patient (ID: TU-4) harboring a hetero-
zygous COL1A1 variant: c.461G > T, p.(Gly154Val).
Available clinical data of this 25 year old male patient are
unfortunately scarce. The diagnosis of PCG was made in
the first 4 years of life based on the presence of Haab’s
striae. In addition, it was reported that he underwent a
cataract surgery. As we do not have more detailed clinical
data concerning the diagnosis of this patient we cannot
exclude also to be in presence of a different form of glau-
coma i.e. infantile glaucoma. Anyway, at the time of the
diagnosis of PCG with cataract, clinical findings concern-
ing OI have been not recorded.
All the parents of these last three patients (MZ-2, CA-3
and TU-4) were unavailable both for clinical reports and
genetic testing, thus no familial segregation could be stud-
ied. For these three patients the sequence chromatograms
of the identified variants are reported in Additional file 2.
Four of the five mutations identified (p.(Gly253*),
p.(Met264Leu), p.(Ala1083Thr) and p.(Gly767Ser)) are
already reported in genetic variant database dbSNP
(rs72645318, rs374947065, rs372029024 and rs72651658
respectively) [44] and three (p.(Gly253*), p.(Ala1083Thr)
and p.(Gly767Ser)) also in the Osteogenesis Imperfecta
(OI) Variant Database [45]. The fifth mutation p.(Gly154-
Val) is not yet reported, both in dbSNP and OI Variant
Database (Table 2). However, at position Gly154 a change
into a stop codon and into alanine is already reported in
both databases.
Following these findings in COL1A1, all four present
patients were additionally screened for mutations in
FOXC1, PITX2 and PAX6. No further variants were de-
tected in these genes. Additionally, MLPA analysis could
exclude allele deletion/insertion in CYP1B1, COL1A1,
FOXC1, PITX2 and PAX6.
Molecular modeling
All affected amino acid positions identified are evolution-
ary conserved among orthologues indicating severe func-
tional restriction at these positions (Fig. 3). Molecular
modeling predicts that the three missense mutations affect
either residues relevant for the collagen alpha-1(I) chain
hetero-trimer stabilization (Gly154, Gly767) or residues
relevant for collagen protein-protein interactions (Met264
and Ala1083) (Fig. 4).
The amino acids glycine (Gly) 154 and 767 are located
in regular triple-helical segments of collagen alpha-1(I)
chain (Fig. 4a, c). Gly positions are strictly conserved in
the collagen proteins because it is the only amino acid
lacking a side chain thus allowing the narrow association
of collagen fibers within the heterotrimeric complex,
facilitating inter strand hydrogen bonding. In the
p.(Gly154Val) mutant, the larger side chain of valine
(Val) cannot be accommodated at this sequence pos-
ition resulting in severe clashes with adjacent amino
acids (Fig. 4b). The same effect is also observed for
the p.(Gly767Ser) mutant (Fig. 4d). Both amino acids
exchanges are therefore predicted to impair the cor-
rect folding of the collagen triple-helix, a well-known
pathomechanism in OI.
Amino acid methionine (Met) at position 264 is lo-
cated within the fibronectin binding site of the collagen
alpha-1(I) chain protein [37]. At this position Met 264
forms tight sidechain packing interactions with the
tryptophan (Trp) 553 of fibronectin (Fig. 4e). These in-
teractions are lost when Met 264 is substituted by the
Cγ-branched sidechain amino acid leucine (Leu) which
forms steric clashes with Trp553. These clashes are
thus predicted to decrease the binding affinity of the
collagen alpha-1(I) chain protein with fibronectin
(Fig. 4f ). The amino acid alanine (Ala) at position 1083,
located immediately adjacent to arginine (Arg) 1084, is
part of a high-affinity recognition consensus site for
protein chaperone Hsp47. Arg1084 in collagen protein
forms a salt-bridge with the aspartic acid (Asp) at pos-
ition 385 of Hsp47 protein (Fig. 4g) which is crucial for
the binding between the two proteins. Substitution of
Ala1083 by threonine at position 1083 has two effects
due its bulkier sidechain containing a hydroxyl-group.
The first effect is to cause some steric clashes with
Leu381 and the second to interfere with the hydrogen
bond formed by amino acids Arg1084-Asp385 (Fig. 4h).
Both effects are expected to decrease the interaction of
the collagen alpha-1(I) chain with Hsp47.
Table 2 COL1A1 variants identified in four glaucoma cases and related phenotype








ExAC_Eur db SNP OI Database
MI-1 Eur M PCG 4 months Retinal detachment no p.(Met264Leu) 6,631E-05 rs374947065 no
p.(Ala1083Thr) 1,477E-05 rs372029024 yes
MZ-2 Eur M JOAG 29 years Cataract yes p.(Arg253*) 0 rs72645318 yes
CA-3 Eur (Am) F JOAG/POAG n/a yes p.(Gly767Ser) 0 rs72651658 yes
TU-4 Eur M PCG/Infantile
glaucoma
4 years Cataract no p.(Gly154Val) 0 no no
Ethnicity: Eur European, Am American, Gender: F female, M male; Glaucoma Type: PCG primary congenital glaucoma, JOAG juvenile open angle glaucoma, POAG
primary open angle glaucoma, OI osteogenesis imperfecta, ExAC_Eur Exome Aggregation Consortium European
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Discussion
The collagen alpha-1(I) chain protein belongs to the col-
lagen complex superfamily in which each component
has a specific function, or set of functions, and there are
extensive interactions with other connective tissue com-
ponents [46]. Thus the clinical phenotypes resulting
from collagen mutations are wide-ranging in their mani-
festations and severity [47]. Of the 28 known vertebrate
collagen types, type I collagen is the most abundant and
widely expressed collagen in humans. It is a heterotrimer
comprising two alpha 1 (I) chains and one alpha 2 (I)
chain. The alpha 1 (I) and alpha 2 (I) chains of type I
collagen are encoded at the unlinked loci COL1A1 and
COL1A2, respectively [48]. The most striking feature of
these alpha chains is that they consist of repeating Gly-
Xaa-Yaa tri-peptides motifs. The presence of glycine
every third amino acid is essential to allow the alpha
chain to adopt the characteristic collagen triple helix.
The mutation profiles of these genes are not restricted
to any specific region but are scattered throughout the
entire structural domains and show enormous diversity.
So far, more than 800 mutations have been reported only
for COL1A1 [45], mainly associated with skeletal and
dermatological conditions such as OI, Ehlers-Danlos
syndrome (EDS), bone mineral density variation, osteo-
porosis and Caffey disease. However, in the literature
there are different descriptions in which both OI and
EDS patients present also a variety of ocular abnormal-
ities. Characteristic ocular findings described are usually
blue sclera, thin cornea, microcornea, myopia, keratoco-
nus, congenital absence of Bowman’s layer, retinal detach-
ment, glaucoma [49–51]. This is not surprising since up
to 80 % of eye tissues are composed of different collagen
proteins, and the most abundant is the type I collagen, in
particular in cornea, sclera, iris, ciliary body, trabecular
meshwork and optic nerve [52]. Additionally, genome
wide association studies (GWAS) have shown that vari-
ants at collagen-related genes, including COL1A1, influ-
ence one of the main glaucoma risk factor such as central
corneal thickness (CCT) [53, 54].
Mutations in certain collagen genes have also been as-
sociated with glaucoma manifesting as part of a systemic
disorder. Stickler syndrome (STL, OMIM 108300), for
example, is a group of diseases primarily caused by mu-
tations in the fibril-forming collagen type II gene.
Mutations causing premature stop codons in exon 2 of
COL2A1 lead to ocular-only phenotypes including ret-
inal detachment and high myopia, but with few or no
other systemic manifestations [55]. A recent GWAS
study found significant association of a single nucleotide
polymorphism in COL11A1 with primary angle-closure
glaucoma [56]. Further, genetic variants in collagen XV,
alpha 1 (COL15A1) and collagen XVIII, alpha 1 (COL18A1)
have been shown to modify the age of onset of both JOAG
and POAG [57].
Collagen proteins are also a pivotal component of
the extracellular matrix (ECM) of the TM, Schlemm’s
canal (SC) and lamina cribrosa (LC), which represent
the ocular tissues involved in glaucoma development.
Morphological and ultrastructural ECM changes involving
elastic-fibers and microfibrils have been already implicated
in glaucoma pathogenesis [58]. In addition, mutations in
multiple genes encoding elastic microfibril components
have been linked to glaucoma [59]. For example, fibrillin-1
(FBN1) mutations cause Marfan syndrome (OMIM
154700) and ocular abnormalities including ectopia lentis,
myopia and glaucoma [49, 60]. Mutations in LTBP2,
which binds to fibrillin-containing microfibrils, cause not
only PCG, but also POAG and pseudoexfoliation glau-
coma [61, 62]. Altogether, these observations underline
the importance of collagen genes, including COL1A1, in
the eye and their putative role in glaucoma pathogenesis.
Nevertheless, except for a recent report by Wallace et al.,
[15] there is no detailed documentation about the associ-
ation of COL1A1 mutations and glaucoma with and/ or
without sign of OI and EDS.
In the present study we describe COL1A1 variants in
four patients associated with different glaucoma forms:
two presenting with PCG, two with JOAG and/or an
early form of POAG. Both patients with early form of
open angle glaucoma present also a diagnosis of OI: in
particular a mild OI type I in the MZ-2 patient, while
the third patient CA-3 has a more severe but not classi-
fied OI form (Table 2).
Of particular interest is the novel finding of COL1A1
compound heterozygous variants (p.(Met264Leu) and
p.(Ala1083Thr)) in the patient MI-1 presenting a novel
phenotype of PCG, retinal detachment and light liga-
ments laxity (Table 2). Molecular modelling suggests
that these two amino acid changes impair the collagen
Fig. 3 Multiple sequence alignments of human COL1A1 region to orthologous. The alignment encompasses the affected amino acid residues (in Bold)
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protein complex interaction with two different binding
proteins: Hsp47 and fibronectin. Thus, the mechanism
of these two variants is different from the one of the
most frequently reported missense variants causing
mainly OI and EDS that is usually dominant and affects
the formation and stabilization of the collagen alpha-1(I)
chain triple-helix itself similarly to the case of our three
other patients described (Table 2). Instead, in the reces-
sive mode the collagen alpha-1(I) chain protein interac-
tions with binding partners seem to be affected. Hsp47
Fig. 4 Structural effect of detected mutations in COL1A1. a Gly154 is located in a regular triple-helical collagen segment. The two glycines
belonging to the COL1A1-chains are shown in space-filled presentation and are labelled. b In the Gly154Val variant, the larger valine sidechain
cannot be accommodated at this sequence positions resulting in several severe clashes with the adjacent amino acids (indicated by black
arrows). c Gly767 is located in a triple-helical collagen segment. The two glycines belonging to the COL1A1-chains are shown in space-filled
presentation and are labelled. d In the Gly767Ser variant, the larger serine sidechain cannot be accommodated at this sequence positions resulting in
several severe clashes with the adjacent amino acids (indicated by black arrows). e Met264 belongs to a stretch of COL1A1 that is recognized
by fibronectin. Met264 forms tight sidechain packing interactions with Trp553 of fibronectin. Both residues are shown in space-filled presentation; the
remaining residues of COL1A1 are shown in stick presentation (atom-type coloring) and fibronectin is shown as blue ribbon. f In the Met264Leu
variant, the Cγ-branched leucine sidechain forms steric clashes (black arrow) with Trp553, which are expected to decrease binding affinity.
g Ala1083 is located immediately adjacent to Arg1084, which confers the consensus of a high-affinity recognition site for the chaperone
Hsp47 that is essential for the proper assembly of the triple-helical procollagen molecules. The collagen triple-helix is shown in red, green,
and blue; the two bound Hsp47 molecules are depicted in blue and cyan. Arg1084 of collagen and Asp385 of Hsp47 form a salt-bridge
that is crucial for high-affinity binding. The residues are shown in stick and their interaction is highlighted by an orange circle. Ala1083 of
collagen forms a weak sidechain interaction with Leu381 of Hsp47 (residues in space-filled presentation). h In the Ala1083Thr variant, the
bulkier threonine sidechain causes steric clashes with Leu381 (black arrow). Further, Ala1083 sidechain hydroxyl group is positioned close
to Arg1084 (orange arrow), which might interfere with the Arg1084-Asp385 hydrogen bond. Both effects are expected to decrease the
collagen-Hsp47 interaction
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is important for the proper assembly of the triple-helical
procollagen molecules and has an important role in eye
morphogenesis [38]. Fibronectin has been found to be
expressed in TM, ciliary body, choroid, basement mem-
brane of the corneal epithelium, corneal stroma and
Descemet’s membrane. It has been shown to be essential
in cornea morphogenesis and in stabilizing the vitreoret-
inal attachment [63]. Impaired binding of collagen protein
to Hsp47 and fibronectin could thus affect the correct for-
mation of eye tissues important for outflow, IOP regula-
tion and retinal attachment. Thus our results suggest that
concomitant impairment of both copies of COL1A1 with
respective binding proteins could influence at a very early
stage the development of the eye more than other tissues.
This might explain the more severe ocular phenotype ob-
served in patient MI-1 compared to the other patients car-
rying variants with dominant effect.
Although, so far COL1A1 gene mutations in humans
are overwhelmingly dominant in their action, there is a
single example of a recessively-inherited case of OI
caused by a homozygous missense mutation in COL1A2
gene [64]. Remarkably, three studies on transgenic mice
with targeted missense mutations in COL1A1 (not-af-
fecting positions of amino acid Gly in the triple-helices)
revealed a glaucoma-like phenotype supporting the caus-
ality of the variants identified in our patient. The mice
developed sustained elevation of IOP, progressive optic
nerve damage and showed a reduced outflow facility. In
addition, they do not present typical clinical signs of OI
and EDS like in our first patient. Further, the heterozy-
gous mice carriers have been reported to be without any
signs of OI and glaucoma similar phenotype as the par-
ents of our MI-1 patient analyzed [14, 65, 66].
The p.(Arg253*) identified in patient MZ-2 intro-
duces a premature stop codon in the COL1A1 gene
coding sequence. This mutation has been previously
reported in a 13 year old patient diagnosed with a
mild form of OI and blue sclera [67]. Glaucoma was
not described for that patient maybe due to the earlier
age (13 years) compared to the onset age of 29 years
in our MZ-2 patient with JOAG and mild OI form. A
large number of frameshifts/nonsense mutations in
this gene have been reported to be associated with
the mild OI type I, following classical dominant in-
heritance. Frameshift and nonsense sequence variants
usually result in nonsense mediated decay (NMD) of
affected transcripts leading to a reduced levels of
mRNA. In practice, this means that little or no trun-
cated protein product is formed resulting in the pro-
duction of about half the amount of normal type I
collagen [68]. Decreased amount of collagen alpha-
1(I) chain protein in the eye could thus explain the
thin and abnormal sclera and the glaucoma detected
in our patient MZ-2.
The mutation identified in patient CA-3 and TU-4
removes a glycine (Gly) at position 154 and 767 introdu-
cing a valine (Val) and serine (Ser) respectively. Mutations
affecting glycine position which produce an abnormal col-
lagen protein are usually reported in more severe pheno-
types than nonsense do. This could explain the presence
of a severe OI form in the patient CA-3 in which bone de-
formities started already in adolescence and the presence
of a congenital glaucoma in the fourth patient identified.
Clinical signs of OI or EDS for this last patient, TU-4,
were not yet reported maybe due to the early age of the
patient’s glaucoma diagnosis (4 years).
We suggest that the range of COL1A1 mutations pre-
senting as either dominant or recessive differentially affect
the collagen alpha-1(I) chain protein function resulting in
a spectrum of connective tissue related phenotypes of
varying severity including glaucoma features as recently
proposed [15]. Nevertheless, we cannot exclude the pos-
sible presence of unidentified genetic variants located out-
side the regions covered by WES, acting in concert with
COL1A1 to modulate the phenotype.
One of the possible limitations of this study due to the
rareness of these combined phenotypes could be the small
number of affected people screened. A further limitation
might be also the absence of unaffected relatives in the
three patients, carriers of single heterozygous variants, to
prove the dominant inheritance and penetrance of these
variants. However, taking into account that these variants
are extremely rare (Table 2) and that they show a putative
impairing effect on the protein function (Fig. 4), we can
suggest that these are probably pathogenic. Undoubtedly,
it is necessary widening the screening of COL1A1 in dif-
ferent, larger cohort of patients with glaucoma and add-
itionally also OI to replicate and confirm these findings.
Conclusions
In summary, the present data together with the recent lit-
erature support and expand the role of COL1A1 in the eye
pathology suggesting a putative role in different forms of
glaucoma. Screening of COL1A1 in larger cohorts of
patients with different forms of glaucoma would be now
necessary to establish a detailed phenotype-genotype cor-
relation. On the other side, also patients with different
forms of OI and EDS should be regularly subjected to
ophthalmologic examination lifelong not only to prevent
irreversible ocular damages but also to have a correct esti-
mate about glaucoma prevalence in these disorders.
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